Matthew J. Maurer, DMSc
@MaurerStats
Followers
2K
Following
3K
Statuses
4K
Associate Professor of Biostatistics & Medicine at Mayo Clinic, #lymphoma researcher #lymsm. Husband; dad of 3. Tweets mine. He/him.
Rochester, MN
Joined December 2013
RT @JohnPLeonardMD: We have several scenarios in chronic #lymphomas where A+B is standard and active agent C being added (AB vs ABC) in a P…
0
17
0
RT @BiostatGirl: First ever statistician meet up at #ASH24! Appreciate that @ASH_hematology is working to foster broader statistician engag…
0
4
0
RT @DrCarlaCasulo: Thank you @JohnPLeonardMD for recognizing our important work in #FL made possible with colleagues from many #LEO centers…
0
5
0
RT @JohnPLeonardMD: Number 1 #LeonardList #ASH24 top #lymphoma abst1 652 – Casulo – POD24 w/&w/o hist transformation (HT) in pt w/FL. 308 p…
0
2
0
RT @JohnPLeonardMD: Presenting #LeonardList #ASH24 top #lymphoma abstracts daily countdown – Number 1 – 1652 – Casulo – Outcomes in early r…
0
2
0
RT @JohnPLeonardMD: My annual #LeonardList @WeillCornell #CancerCast episode is back for the 7th year. Tune in to hear my top 10 abstract (…
0
14
0
RT @CaThompsonMD: Come work with us! We are looking for a lymphoma physician to join our Lymphoid Malignancies Disease Group at Mayo Clinic…
0
4
0
RT @Othman_Al_Sawaf: Check out our latest paper in @JCO_ASCO on surrogacy of endpoints in 1L #CLL trials! Led by @Sim_Florian, we systemat…
0
23
0
RT @Lymphoma_Doc: Great week at @ASH_hematology Clinical Research Training Institute. Congrats to our rising stars - the future is bright!…
0
2
0
RT @BiostatGirl: The stat/epi crowd at #ASHCRTI! PSA: Treat your biostatistician well — they are important to your hematology research care…
0
1
0
RT @ComeBommier: FINALLY OUT ! "What clinicians should know about surrogate end points in hematologic malignancies" A clinician-friendly…
0
7
0
If efficiency is desired, then again figures are vital. A savvy reviewer can immediately spot data/analytical errors from a figure that would not be easily (or at all) determined from text. I worry this is not going to go well for abstract review... #ASH24 @ASH_hematology #lymsm
1
2
9
I agree there was lots of inconsistency in the following the image guidelines. This seems a bit too far a correction vs penalties for those who don’t follow abstract guidelines. I would always prefer to see a KM curve vs simply reporting HRs. @ASH_hematology #ASH24
2
2
15
RT @FDAOncology: 🎇 Today, Sunday, May 5 - #CincodeMayo - We officially launch Project 5 in 5: Crowdsourcing 5 clinically relevant questions…
0
8
0
RT @Maryam_Yazdy: 🎇 Today, Sunday, May 5 - #CincodeMayo - We officially launch Project 5 in 5: Crowdsourcing 5 clinically relevant question…
0
1
0
RT @GSCollins: Some red flags when reading a prediction model paper - no sample size calc - no mention of missing data - dichotomania - an…
0
77
0
RT @Blood_Cancers: The FDA ODAC voted in favor of the use of MRD-negativity as an endpoint for accelerated approval in #myeloma trials. Re…
0
3
0
@Eddie_Cliff @ComeBommier @BloodJournal Thanks Eddie. @ComeBommier did a great job putting this together and writing a clinician oriented take on the topic.
1
0
5
RT @Eddie_Cliff: What clinicians should know about surrogate endpoints Nice work @ComeBommier @MaurerStats Many great examples woven int…
0
20
0